Evidence map›Paper›PMID 33205337›Full record

Trial reportAnnals of hematology2021

Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.

Jae-Cheol Jo, Jin-Seok Kim, Je-Hwan Lee, Jung-Hee Lee, Seong Nam Im, Sang-Min Lee, Sung-Soo Yoon, In-Ho Kim, Seong Hwa Bae, Yoo Jin Lee and 2 more

Open access · greenAbstract readClinical TrialMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.ORCID http://orcid.org/0000-0001-6014-7977
Jin-Seok KimDepartment of Internal Medicine, Severance Hospital, Yeonsei University College of Medicine, Seoul, Korea.
Je-Hwan LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jung-Hee LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Seong Nam ImDepartment of Hematology and Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Sang-Min LeeDepartment of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. ssysmc@snu.ac.kr.
In-Ho KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Seong Hwa BaeDepartment of Hematology and Oncology, Daegu Catholic University Hospital, Daegu Catholic University School of Medicine, Daegu, Korea.
Yoo Jin LeeDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Yunsuk ChoiDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Won-Sik LeeDepartment of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. wonsik112@gmail.com.
Ulsan College · KRInje University Busan Paik Hospital · KRSeoul National University Hospital · KRDaegu Catholic University · KRInje University Haeundae Paik Hospital · KRSeverance Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the unsatisfactory survival in patients who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for peripheral T-cell lymphomas (PTCLs), we conducted a prospective trial of busulfan (Bu), etoposide (E), cytarabine (A), and melphalan (M) (BuEAM), including IV Bu instead of carmustine (BCNU) as in standard BEAM, as a high-dose regimen in such patients. This study evaluated the efficacy and toxicity of BuEAM as a high-dose regimen for ASCT in patients with T-cell lymphomas. The high-dose chemotherapy at seven centers in Korea included Bu (3.2 mg/kg IV qd from day 6 to day 5), E (200 mg/m

Indexed as

AdultAgedAntineoplastic Agents, AlkylatingAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBusulfanCytarabineDose-Response Relationship, DrugEtoposideFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, T-Cell, PeripheralMaleMelphalanMiddle AgedAntineoplastic Agents, AlkylatingAntineoplastic Agents, PhytogenicBusulfanCytarabineEtoposideMelphalanAutologous stem cell transplantationHigh-dose regimenT-cell lymphomas

Identifiers

PMID33205337
OpenAlexW3101861760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.